Lancet Commission: Stem cells and regenerative medicine

Cossu, Giulio; Birchall, Martin A.; Brown, Terry; Coppi, Paolo De; Culme-Seymour, Emily; Gibbon, Sahra; Hitchcock, Julian; Mason, Chris; Montgomery, Jonathan; Morris, Stephen; Muntoni, F.; Napier, David; Owji, Nazanin; Prasad, Aarathi; Round, Jeff; Saprai, Prince; Stilgoe, Jack; Thrasher, Adrian J.; Wilson, James

doi:10.1016/s0140-6736(17)31366-1

Cited by 216 publications

(207 citation statements)

References 149 publications

Supporting

Mentioning

204

Contrasting

Unclassified

Order By: Relevance

“…Cossu et al . ). This assumes that ‘facts’ will necessarily carry most authority in credibility contests and provide the foundation for engendering public trust.…”

Section: Discussionmentioning

confidence: 97%

“…While clinical successes thus far are limited to the use of blood stem cells for the treatment of many types of cancers and diseases of the blood and immune system, and a small number of other applications that capitalise on the presence of stem cells in skin and the surface of the eye, scientific and public optimism for stem cell science remains high, especially with frequent media reports of ‘breakthroughs’, leading to ‘gaps’ between people's expectations and clinical practice (Cossu et al . : 1). In Cossu, et al .…”

Section: The Internet and The Advertising Of Sctsmentioning

confidence: 95%

“…Regulation of this market has proved difficult for various reasons, including its complex character involving opaque and sometimes highly mobile national and transnational actors, the political and practical difficulty of harmonising and coordinating multiple regulatory agencies, regulatory exemptions regarding autologous SCTs in some jurisdictions, the myriad array of claimed stem cell products for a huge range of conditions, and the multiple sources and means by which information on treatments may be procured (Cossu et al . , Sleeboom‐Faulkner et al . ).…”

Section: The Internet and The Advertising Of Sctsmentioning

confidence: 99%

See 2 more Smart Citations

Navigating the cartographies of trust: how patients and carers establish the credibility of online treatment claims

Petersen

Tanner

Munsie

2019

Sociology Health & Illness

View full text Add to dashboard Cite

Digital media offer citizens novel ways of ‘enacting’ health and illness, and treatment and care. However, while digital media may so ‘empower’ citizens, those searching for credible information will be confronted with various, often‐conflicting claims that may have ‘disempowering’ effects. This article uses Gieryn's concept of the ‘cultural cartography’ to explore the criteria that patients and carers employ in establishing the credibility of information on alleged treatments. Drawing on data from interviews with Australian patients and carers who have travelled or considered travelling abroad for unproven commercial stem cell treatments, the article examines how individuals assess rival sources of epistemic authority – science‐based and non‐science‐based – as they search for credible information. As we argue, in a context where conventional treatment options are perceived to be limited or non‐existent – which is likely to be the case with those suffering severe, life‐limiting conditions – and the credibility of sources uncertain, matters of opinion and belief are prone to being interpreted as matters of fact, with potentially far‐reaching implications for citizens’ health. Revealing the mechanisms by which individuals ascribe credibility to health information, we conclude, has become crucial as digital media assume a growing role in health and healthcare and governments encourage citizens to become ‘digitally literate’.

show abstract

“…Cossu et al . ). This assumes that ‘facts’ will necessarily carry most authority in credibility contests and provide the foundation for engendering public trust.…”

Section: Discussionmentioning

confidence: 97%

Section: The Internet and The Advertising Of Sctsmentioning

confidence: 95%

Section: The Internet and The Advertising Of Sctsmentioning

confidence: 99%

See 1 more Smart Citation

Navigating the cartographies of trust: how patients and carers establish the credibility of online treatment claims

Petersen

Tanner

Munsie

2019

Sociology Health & Illness

View full text Add to dashboard Cite

show abstract

“…By 2008, several groups had adopted the technique, generating iPSCs that were considered epigenetically [44] and developmentally [45] indistinguishable from ESCs of murine [46], nonhuman primate (NHP) [47] and human origin [48,49]. To this day, pluripotent stem cell approaches to regenerative medicine have been proposed to address afflictions from cystic fibrosis [51][52][53] to diabetes [54][55][56] to third-degree burns [57][58][59]. To this day, pluripotent stem cell approaches to regenerative medicine have been proposed to address afflictions from cystic fibrosis [51][52][53] to diabetes [54][55][56] to third-degree burns [57][58][59].…”

Section: Pluripotent Cell Reprogrammingmentioning

confidence: 99%

Haematopoietic stem cell reprogramming and the hope for a universal blood product

2019

View full text Add to dashboard Cite

Edited by Catherine RobinHaematopoietic stem cells (HSCs) are the only adult stem cells with a demonstrated clinical use, even though a tractable method to maintain and expand human HSCs in vitro has not yet been found. Owing to the introduction of transplantation strategies for the treatment of haematological malignancies and, more recently, the promise of gene therapy, the need to improve the generation, manipulation and scalability of autologous or allogeneic HSCs has risen steeply over the past decade. In that context, reprogramming strategies based on the expression of exogenous transcription factors have emerged as a means to produce functional HSCs in vitro. These approaches largely stem from the assumption that key master transcription factors direct the expression of downstream target genes thereby triggering haematopoiesis. Both somatic and pluripotent cells have been used to this end, yielding variable results in terms of haematopoietic phenotype and functionality. Here, we present an overview of the haematopoietic reprogramming methods reported to date, provide the appropriate historical context and offer some critical insight about where the field stands at present.

show abstract

“…Like a house, after many years, our body needs repair or even a flip. Regenerative medicine is a promising strategy to repair and rebuild our own body, by creating new tissues to restore or replace organ function lost [1]. Regenerative medicine also empowers scientists and bioengineers to manufacture tissues and organs in the laboratory implantation.…”

Section: Introduction: Building Blocks For Regenerative Medicinementioning

confidence: 99%

Body builder: from synthetic cells to engineered tissues

Ogle

Cheng

2018

Current Opinion in Cell Biology

View full text Add to dashboard Cite

It is estimated that 18 Americans die every day waiting for an organ donation. And even if a patient receives the organ that s/he needs, there is still >10% chance that the new organ will not work. The field of tissue engineering and regenerative medicine aims to actively use a patient's own cells, plus biomaterials and factors, to grow specific tissues for replacement or to restore normal functions of that organ, which would eliminate the need for donors and the risk of alloimmune rejection. In this review, we summarized recent advances in fabricating synthetic cells, with a specific focus on their application to cardiac regenerative medicine and tissue engineering. At the end, we pointed to challenges and future directions for the field.

show abstract

Lancet Commission: Stem cells and regenerative medicine

Cited by 216 publications

References 149 publications

Navigating the cartographies of trust: how patients and carers establish the credibility of online treatment claims

Navigating the cartographies of trust: how patients and carers establish the credibility of online treatment claims

Haematopoietic stem cell reprogramming and the hope for a universal blood product

Body builder: from synthetic cells to engineered tissues

Contact Info

Product

Resources

About